Jean-Francois Formela

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA.

Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Proprius Pharmaceuticals, Inc. develops, commercializes and markets pharmaceutical products. It provides personalized medicine services to rheumatologists. The company's product pipeline includes two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded by Michael J. Walsh in 2005 and is headquartered in San Diego, CA.

Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ.

Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA.

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA.

Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France.

NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. The Services segment includes revenues from dialysis services provided to patients at its recently opened NxStage Kidney Care dialysis centers. The company was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Waltham, MA.

Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom.

UCSD Athena operates as an organization for executive women in science, technology and healthcare. The company is headquartered in La Jolla, CA.

The Massachusetts General Hospital Clinical Research Program promotes clinical research, translational clinical trials, epidemiology, outcomes, and disease management programs. The private company is based in Boston, MA.

The Institute of Contemporary Art (ICA) is an organization dedicated to promoting experimentation in contemporary art, advancing new scholarship, and fostering the exchange of art and ideas. The non-profit company is based in Miami, FL. Through exhibitions, programs, and its collection, ICA provides an international platform for the work of local, emerging, and under-recognized artists, and advances the public appreciation and understanding of innovative art. ICA was launched in 2014 and opened its new permanent home in Miami's Design District on December 1, 2017.

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.

Part of GSK Plc, Cellzome, Inc. develops immune-inflammation therapy. The private company is based in Philadelphia, PA. The company was founded by Spyridon Artavanis-Tsakonas, Stelios Papadopoulos.

CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA.

Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts.

Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA.

Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.

Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA.

Ifm Therapeutics, Inc. develops immunotherapy that focuses on targeting the adaptive immune system. The private company is based in Boston and was founded by Jean-Francois B. Formela.